- Home
- RVMD vs OMC Comparison
RVMD vs OMC Comparison
Compare RVMD & OMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | OMC |
|---|---|---|
| Founded | 2014 | 1944 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 21.9B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | RVMD | OMC |
|---|---|---|
| Price | $141.72 | $78.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 7 |
| Target Price | ★ $139.58 | $98.71 |
| AVG Volume (30 Days) | 3.2M | ★ 3.9M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.10% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,271,900,000.00 |
| Revenue This Year | N/A | $46.93 |
| Revenue Next Year | $533.02 | $0.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.09 |
| 52 Week Low | $34.00 | $66.33 |
| 52 Week High | $155.70 | $87.17 |
Technical Indicators
Market Signals| Indicator | RVMD | OMC |
|---|---|---|
| Relative Strength Index (RSI) | 70.85 | 54.19 |
| Support Level | $93.39 | $76.91 |
| Resistance Level | N/A | $80.90 |
| Average True Range (ATR) | 6.14 | 1.76 |
| MACD | 3.93 | 0.40 |
| Stochastic Oscillator | 78.18 | 67.57 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About OMC Omnicom Group Inc.
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, ad placement, and public relations. The firm operates globally, providing services in more than 70 countries; it generates more than one half of its revenue in North America and nearly 30% in Europe.